AP NEWS

Human Growth Hormone Drugs - Global Strategic Business Report 2018: Innovations Hold the Key to Market Growth - ResearchAndMarkets.com

July 9, 2018

DUBLIN--(BUSINESS WIRE)--Jul 9, 2018--The “Human Growth Hormone Drugs - Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets.

This report analyzes the worldwide markets for Human Growth Hormone Drugs in US$ Million.

The report profiles 28 companies including many key and niche players such as:

Eli Lilly and Company (US) Ferring Holding SA (Switzerland) Genentech, Inc. (US) GeneScience Pharmaceuticals Co., Ltd. (China) Merck KGaA (Germany) Novo Nordisk A/S (Denmark) Pfizer, Inc. (US) Sandoz International GmbH (Germany)

Key Topics Covered

1. INDUSTRY OVERVIEW

2. MARKET TRENDS & ISSUES

Pediatric GHD Rules, while Adult GHD Remains Underserved Long-Acting hGH Drugs - A Potential Game Changer Select Long-Acting hGH Products in Pipeline by Development Stage Biosimilars Create Little Impact, Further Validation to Expand Indications and Growth Manufacturers Bet on Novel Drug Delivery Technologies Phase IV Studies Necessitated for First Biosimilars Needle-less Drug Delivery Systems to Wipe Out of Syringes Drug Delivery Device Options for Marketed hGH Products Growing Non-Prescription/Off-Label Usage - A Potential Health Hazard Oral hGH Secretagogues - An Alternative to Controversial hGH Injections in Professional Sports Risk of Cancer Necessitates Judicious Use of hGH in Children Dose Titration - A Key to Achieve Enhanced Tolerability Growth Concerns about Prolonged Usage of Growth Hormones

3. COMPETITIVE LANDSCAPE

4. HUMAN GROWTH HORMONE: AN OVERVIEW

5. RECENT INDUSTRY ACTIVITY

6. FOCUS ON SELECT GLOBAL PLAYERS

7. GLOBAL MARKET PERSPECTIVE

Total Companies Profiled: 28 (including Divisions/Subsidiaries 33)

The United States (10) Canada (1) Japan (2) Europe (10) Germany (4)The United Kingdom (2)Rest of Europe (4) Asia-Pacific (Excluding Japan) (9) Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/kpntl7/human_growth?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005543/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 07/09/2018 10:12 AM/DISC: 07/09/2018 10:12 AM

http://www.businesswire.com/news/home/20180709005543/en

AP RADIO
Update hourly